Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Vedolizumab Subcutaneous Long-Term Open-Label Extension Study